What is Allos?
Allos AI is at the forefront of pharmaceutical innovation, utilizing Causal AI to transform existing complex drugs into more bioavailable, safer, and easier-to-take medicines. Founded by a multidisciplinary team comprising an Oxford-trained quantum physicist, applied AI researchers, and industry veterans in complex generics, Allos merges profound scientific expertise with practical drug development experience. The AI-native company specializes in reformulating small-molecule drugs and designing clinical studies grounded in real-world evidence derived from health records. This approach aims to bring molecules to market with increased speed and confidence, enabling collaborations with pharmaceutical companies to modernize legacy assets, unlock stalled programs, and expand access to complex generics.
How much funding has Allos raised?
Allos has raised a total of $5M across 1 funding round:
Seed
$5M
Seed (2026): $5M with participation from Berkeley SkyDeck Fund, Habico Invest, and Oxford Sciences Enterprises
Key Investors in Allos
Berkeley SkyDeck Fund
Berkeley SkyDeck Fund is a premier startup accelerator program affiliated with the University of California, Berkeley, offering investment, mentorship, and network access to early-stage startups. It provides tailored support, including significant investment and connections to venture capitalists, with a commitment to fostering diversity and inclusion.
Habico Invest
Habico Invest A/S is a Danish family office specializing in investments across a wide range of asset classes, providing tailored strategic investment solutions aimed at enhancing financial growth for its clients.
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent investment company established in 2015, focused on founding, funding, and building transformational businesses through a unique partnership with the University of Oxford.
What's next for Allos?
The recent major strategic investment signals a new phase of growth and expansion for Allos. This capital infusion is expected to fuel further research and development into its Causal AI platform, enhance its capabilities in clinical study design using real-world evidence, and broaden its strategic partnerships within the pharmaceutical industry. The company is well-positioned to address the critical need for modernizing legacy drug assets and improving the accessibility of complex generics, potentially leading to significant advancements in patient care and market penetration.
See full Allos company page
